$90m IPO Sets Up Sweden's Calliditas For Phase III Readout

Biotech Sector Listings Defying Pandemic

The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.

Going public
The Nasdaq IPO gears the company up for a US commercial focus

Swedish specialist pharma company Calliditas Therapeutics AB has exceeded expectations by raising $90m in an upsized initial public offering (IPO) on the NASDAQ exchange.

The flotation is a success for the company, which had been aiming to raise $75m with the IPO. The funds...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip